Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
143.16
+0.16 (0.11%)
Pre-market: 145.00 +1.84 (1.29%)
Feb 10, 7:12AM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 140.82 - 145.63
52 week 130.09 - 181.81
Open 141.02
Vol / Avg. 1,100.00/4.17M
Mkt cap 106.47B
P/E 15.79
Div/yield 1.00/2.79
EPS 9.07
Shares 754.00M
Beta 0.78
Inst. own 82%
Apr 19, 2016
Q1 2016 Amgen Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 10, 2016
Amgen Inc at Leerink Partners Global Healthcare Conference - 9:15AM EST - Add to calendar
Jan 28, 2016
Q4 2015 Amgen Inc Earnings Call - Webcast
Jan 28, 2016
Q4 2015 Amgen Inc Earnings Release
Jan 12, 2016
Amgen Inc at JPMorgan Healthcare Conference (Q&A)
Jan 12, 2016
Amgen Inc at JPMorgan Healthcare Conference - Webcast
Dec 7, 2015
Amgen Inc ASH Investor Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 32.51% 32.03%
Operating margin 36.72% 39.10%
EBITD margin - 39.10%
Return on average assets 10.07% 9.87%
Return on average equity 25.76% 25.77%
Employees 17,900 -
CDP Score - 64 C

Address

1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company's sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company's products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 64
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 60
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 58
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 53
Bio & Compensation  - Reuters
Stuart A. Tross Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 58
Bio & Compensation  - Reuters
Annette Louise Such Chief Accounting Officer
Age: 46
Bio & Compensation  - Reuters